Skip to content

Pere-Joan Cardona

  • MD, PhD
  • Autonomous University of Barcelona
  • 33h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 4056CitationsNumber of citations received by Pere-Joan's publications. Updated daily.

Research interests

Tuberculosis epidemiologyHuman models in DrosophilaMathematical modellingImmunopathologyTuberculosis

About

I’ve been studying TB from an immunopathogenic point of view, using experimental modelling “in vitro”, “in vivo” and “in silico”, as well as using tissues from human origin. I’ve authored different hypothesis to explain it; “Dynamic hypothesis”; “Citadel Paradox”; “Confluent hypothesis”. On 2000 we developed the first therapeutic vaccine against tuberculosis RUTI®, developed by Archivel Farma which has successfully finished a Phase II Clinical trial. Now I’m the leader of MANREMYC (http://www.manremyc.cat), a spin off to develop the first supplement food against TB, based on heat-killed Mycobacterium manresensis, to reduce the risk of suffering TB. Fortunately this will be easily disseminated and will become a definitive tool to control this terrible disease !

Groups

Co-authors (673)

  • Yago Arribas

Recent publications

  • A beneficial effect of low-dose aspirin in a murine model of active tuberculosis

    • Kroesen V
    • Rodríguez-Martínez P
    • García E
    • et al.
    N/AReaders
    0Citations
    Get full text
  • A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis

    • Leung-Theung-Long S
    • Coupet C
    • Gouanvic M
    • et al.
    N/AReaders
    1Citations
    Get full text

Editorships

PLOS One

Academic Editor

2006 - Present

Professional experience

Universitat Autonoma Barcelona